Skip to main content
Publications
Mody FV, Goyal RK, Ajmera M, Cainzos-Achirica M, Davis KL, Lindstrom RC, Globe G, Riebman JB, Wirtz HS, Amin A. Exploring the association between heart rate control and patient outcomes: a retrospective medical record review of patients hospitalized with systolic heart failure. Poster presented at the 2019 Heart Failure Society of America 23rd Annual Scientific Meeting; September 14, 2019. Philadelphia, PA. [abstract] J Card Fail. 2019 Aug; 25(8 Supplement):S156. doi: 10.1016/j.cardfail.2019.07.447
Matharu M, Pascual J, Nisson Remahl I, Straube A, Lum A, Davar G, Odom D, Bennett L, Proctor C, Gutierrez L, Andrews E, Johannes C. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. Cephalalgia. 2017 Dec;37(14):1384-97. doi: 10.1177/0333102417724150
Cronin-Fenton DP, Kjaersgaard A, Norgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sorensen HT. Clinical outcomes of female breast cancer according to BRCA mutation status. Cancer Epidemiol Biomarkers Prev. 2017 Aug;49:128-37. doi: 10.1016/j.canep.2017.05.016
Garratt C, Weatherall M, Pohjanjousi P, Aantao R, Conti G, Lewis M, Moore N, Perez-Gutthann S. A multinational, drug utilisation study to investigate the use of dexmedetomidine (DEXDOR®) in clinical practice in the EU. Poster presented at the 2015 ESICM's 28th Annual Congress; October 3, 2015. Berlin, Germany. [abstract] Intensive Care Med Exp. 2015 Oct 1; 3(Suppl 1):A322. Previously presented at the 31st ICPE International Conference on Pharmacoepidemiology and Therapeutic Risk Management. doi: 10.1186/2197-425X-3-S1-A322
Matharu M, Pascual J, Nilsson Remahl L, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A. Interim analysis of the real-world utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in an observational study in the European Union. Poster presented at the International Headache Conference; May 14, 2015. Valencia, Spain. [abstract] Cephalalgia. 2015; 35(6S):39.
Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, DiCioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PDP, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, VanDenBerg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev. 2008 Dec 1;17(12):3567-72.
Schildkraut JM, Moorman PG, Bland AE, Halabi S, Calingaert B, Whitaker R, Lee PS, Elkins-Williams T, Bentley RC, Marks JR, Berchuck A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev. 2008 Mar 1;17(3):585-93.
Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, Halabi S, Calingaert B, Gusberg A, Marks JR, Berchuck A. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007 Mar 1;16(3):473-80.
Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, Serra C, Carrato A, Lloreta J, Rothman N, Villanueva C, Dosemeci M, Malats N, Silverman D. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1696-702. doi: 10.1158/1055-9965.EPI-06-0038
Fortuny J, de Sanjose S, Becker N, Maynadie M, Cocco PL, Staines A, Foretova L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P. Statin use and risk of lymphoid neoplasms: results from the European Case-Control Study EPILYMPH. Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):921-5. doi: 10.1158/1055-9965.EPI-05-0866 PMID 16702371
Berchuck A, Schildkraut JM, Wenham RM, Calingaert B, Ali S, Henriott A, Halabi S, Rodriguez GC, Gertig D, Purdie DM, Kelemen L, Spurdle AB, Marks J, Chenevix-Trench G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev. 2004 Dec 1;13(12):2141-7.